The prostate cancer
drugs market is expected to nearly double by 2020, due to the introduction of new, more expensive drugs.
The study is the first solid evidence tying shift work to prostate cancer
, says neuroendocrinologist David Blask of the Bassett Research Institute in Cooperstown, N.
Increased clusterin expression protects prostate cancer
cells from the cytotoxic effects of hormone ablation and chemotherapy and elevated levels of clusterin are associated with hormone resistance and metastasis.
Higano (Oncology Specialist, Seattle Cancer Care Alliance and Associate Professor, University of Washington School of Medicine, Seattle); and Mack Roach III (Professor of Radiation Oncology and Urology, Department of Radiation Oncology, University of California, San Francisco), the American Cancer Society's Complete Guide To Prostate Cancer
is a single volume compendium providing the non-specialist general reader with all of the up-to-date information available on prostate cancer
Although arsenic carcinogenesis has many other targets, a significant association has also been observed between prostate cancer
and chronic arsenic-exposure (Chen and Wang 1990; Lewis et al.
It has been a real, real dream for me to do something about the people who suffer from prostate cancer
But prostate cancer
is still expected to strike 230,100 men and claim 29,900 lives this year.
Dairy products, calcium, and prostate cancer
risk in the Physicians' Health Study.
Risk increases with age--approximately 60% of men develop prostate cancer
over time, according to autopsy statistics.
Cytogen Corporation (NASDAQ: CYTO) today reported that clinical investigators from leading cancer research centers presented data from recent and ongoing clinical trials of both PROSTASCINT([R]) (capromab pendetide) and QUADRAMET([R]) (samarium Sm-153 lexidronam injection) in prostate cancer
at the 2007 Prostate Cancer
Symposium, multidisciplinary meeting co-sponsored by the American Society of Clinical Oncology (ASCO), the American Society for Therapeutic Radiology and Oncology (ASTRO), and the Society of Urologic Oncology (SUO) held February 22-24, 2007 in Orlando, Florida.
An overview of prostate cancer
which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
The test may offer advantages over prostate specific antigen (PSA) testing, the current standard for initial prostate cancer
screening in conjunction with a digital rectal exam.